Editas’s EDIT-101 Faces Uncertainty As LCA10 Data Lack BRILLIANCE
Data showed efficacy limited to IVS26-mutant Leber congenital amaurosis 10, which affects only 300 patients in the US. The company is pausing enrollment as it seeks a partner.
Data showed efficacy limited to IVS26-mutant Leber congenital amaurosis 10, which affects only 300 patients in the US. The company is pausing enrollment as it seeks a partner.